In line with previous findings (Riveraet al, 2005), we observed that IGF2 protein levels decline in the hippocampus of the AD brain; this led us to test the hypothesis that IGF2 is a potential treatment for AD in preclinical models. Here, IGF2 is linked to Alzheimer disease.